{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vesiculobullous+Skin+Disease&page=4",
    "query": {
      "condition": "Vesiculobullous Skin Disease",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 148,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vesiculobullous+Skin+Disease&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vesiculobullous+Skin+Disease&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T20:23:11.253Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05838092",
      "title": "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "allo-APZ2-OTS",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RHEACELL GmbH & Co. KG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 9,
      "start_date": "2023-10-18",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05838092"
    },
    {
      "nct_id": "NCT00001150",
      "title": "Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dermatitis",
        "Healthy",
        "Neoplasm",
        "Urticaria",
        "Vesiculobullous Skin Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2000,
      "start_date": "1976-10",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001150"
    },
    {
      "nct_id": "NCT04227106",
      "title": "Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "EB-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abeona Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-01-10",
      "completion_date": "2022-10-18",
      "has_results": false,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 2,
      "location_summary": "Redwood City, California • Worcester, Massachusetts",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04227106"
    },
    {
      "nct_id": "NCT00286325",
      "title": "Rituximab in the Treatment of Patients With Bullous Pemphigoid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2005-03",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2013-04-11",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00286325"
    },
    {
      "nct_id": "NCT00587223",
      "title": "Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa, Junctional",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "Apligraf",
          "type": "DEVICE"
        },
        {
          "name": "Standard dressing regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Organogenesis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-12",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2010-06-29",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Miami, Florida • New York, New York + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587223"
    },
    {
      "nct_id": "NCT05000216",
      "title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis (RA)",
        "Systemic Lupus Erythematosus (SLE)",
        "Pemphigus Vulgaris",
        "Multiple Sclerosis (MS)",
        "Systemic Sclerosis (SSc)",
        "Pediatric SLE",
        "Juvenile Idiopathic Arthritis (JIA)",
        "Juvenile Dermatomyositis (JDM)",
        "Pediatric-Onset Multiple Sclerosis (POMS)"
      ],
      "interventions": [
        {
          "name": "Moderna mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.COV2.S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Continue IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Continue IS (B cell depletion therapy)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent [B.1.351] CoV2 preS dTM-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Withhold IS (MMF or MPA)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Withhold IS (B cell depletion therapy)",
          "type": "DRUG"
        },
        {
          "name": "Moderna mRNA-1273, Bivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-08-13",
      "completion_date": "2024-03-28",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05000216"
    },
    {
      "nct_id": "NCT05681481",
      "title": "A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2023-03-22",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05681481"
    },
    {
      "nct_id": "NCT05843994",
      "title": "Artificial Intelligence Patient App for RDEB SCCs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "online survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-01-30",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05843994"
    },
    {
      "nct_id": "NCT01859780",
      "title": "Visual Distraction as a Means of Enhancing Child Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Unintentional Ingestion of Prescriptions Within Vials and Blisters"
      ],
      "interventions": [
        {
          "name": "Visual distractor",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "54 Months",
        "sex": "ALL",
        "summary": "2 Years to 54 Months"
      },
      "enrollment_count": 229,
      "start_date": "2013-08",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2024-05-03",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 3,
      "location_summary": "East Lansing, Michigan • Howell, Michigan • Toledo, Ohio",
      "locations": [
        {
          "city": "East Lansing",
          "state": "Michigan"
        },
        {
          "city": "Howell",
          "state": "Michigan"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859780"
    },
    {
      "nct_id": "NCT04214002",
      "title": "The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa",
        "DEB - Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-01",
      "completion_date": "2020-02-24",
      "has_results": false,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-10-09T20:23:11.253Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214002"
    }
  ]
}